14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CSAI vs ABVX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Abivax SA (ABVX) captures the overall head-to-head institutional edge over Cloudastructure, Inc. (CSAI) on higher Unified Composite conviction (42.4/100 HOLD vs. 38.7/100 SELL) after splitting the core matrix 5–3 (led by Options & Positioning), while CSAI wins 4–1 across the 6-pillar growth and valuation breakdown. CSAI trades at $0.48 (N/M Forward P/E, -164.2% operating margin) versus ABVX at $73.20 (N/M Forward P/E, -6270.4% operating margin).
Growth vs. Quality Trade-Off: ABVX earns the overall head-to-head edge with a stronger Unified Composite Score (42.4/100 HOLD vs. CSAI 38.7/100 SELL) and 1.55β · 55% Vol risk profile, whereas CSAI leads top-line expansion (+6.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: CSAI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 19.0); meanwhile ABVX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CSAI vs ABVX. Trailing 12-month operating profitability (CSAI -164.2% vs ABVX -6270.4%) and valuation multiples (CSAI N/M vs ABVX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $7.1B market capitalization and -6270.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CSAI vs ABVX Key Questions & Quantitative Answers
As of Nov 20, 2026, Abivax SA (ABVX) captures the overall head-to-head institutional edge over Cloudastructure, Inc. (CSAI) on higher Unified Composite conviction (42.4/100 HOLD vs. 38.7/100 SELL) after splitting the core matrix 5–3 (led by Options & Positioning), while CSAI wins 4–1 across the 6-pillar growth and valuation breakdown. CSAI trades at $0.48 (N/M Forward P/E, -164.2% operating margin) versus ABVX at $73.20 (N/M Forward P/E, -6270.4% operating margin). Growth vs. Quality Trade-Off: ABVX earns the overall head-to-head edge with a stronger Unified Composite Score (42.4/100 HOLD vs. CSAI 38.7/100 SELL) and 1.55β · 55% Vol risk profile, whereas CSAI leads top-line expansion (+6.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CSAI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 19.0); meanwhile ABVX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CSAI leads the Growth & Scale pillar: CSAI posts +6.1% YoY revenue growth and +0.0% YoY earnings growth on $5.9M TTM revenue (36.5% gross margin, -164.2% operating margin), compared with ABVX at -6.8% YoY revenue growth and +0.0% YoY earnings growth on $4.7M TTM revenue (100.0% gross margin, -6270.4% operating margin). On trailing 12-month operating scale, CSAI generates $5.9M in USD-normalized revenue versus $4.7M for ABVX. In operating R&D and SG&A reinvestment, CSAI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABVX.
CSAI screens cheaper on headline valuation multiples. CSAI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (unreported EBITDA margin), whereas ABVX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CSAI (-214.8% ROE) versus ABVX (-252.3% ROE) capital efficiency.
In options market volatility and institutional positioning, CSAI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (15.27β · 183% Vol realized risk). By comparison, ABVX carries 76.9% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 55% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.